Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792729 | 0.91 | MTNR1A (0.50) | SMN1; SMN2NPC1RAB9AMAPTTP53 | |
| SCHEMBL6977453 | 0.79 | DRD2 (0.47) | SMN1; SMN2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL6801822 | 0.79 | DRD2 (0.47) | SMN1; SMN2NPC1RAB9AMAPTMEN1 | |
| SCHEMBL6795325 | 0.78 | MTNR1A (0.49) | SMN1; SMN2NPC1RAB9AMAPTTP53 | |
| SCHEMBL6960133 | 0.77 | DRD2 (0.58) | MAPTMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL6794950 | 0.75 | MTNR1A (0.53) | SMN1; SMN2RAB9AMAPTTP53L3MBTL1 | |
| SCHEMBL6789138 | 0.74 | MTNR1A (0.54) | MAPTL3MBTL1MEN1KMT2AHTT | |
| SCHEMBL6795987 | 0.74 | MTNR1A (0.54) | SMN1; SMN2MAPTTP53MEN1KMT2A | |
| SCHEMBL6795436 | 0.74 | MTNR1A (0.42) | NPC1RAB9AMAPTRECQLDRD2 | |
| SCHEMBL6794807 | 0.73 | MAPT (0.55) | MAPTMEN1KMT2APOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767907-B2 | FOR THERAPY OF PSYCHIC AND NEUROLOGIC DISORDERS | H. LUNDBECK A/S (DK) | 2004-07-27 | — | — | US | disclosed |
| US-6743808-B1 | PSYCHOLOGICAL AND NEUROLOGIC DISORDERS; CENTRAL SEROTONERGIC 5-HT1A AND 5-HT2A RECEPTOR ANTAGONISTS | H. LUNDBECK A/S (DK) | 2004-06-01 | — | — | US | disclosed |
| US-20030195356-A1 | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines | PERREGAARD JENS KRISTIAN (DK) | 2003-10-16 | — | — | US | disclosed |
| US-6218394-B1 | FOR THERAPY OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, SUCH AS GENERALISED ANXIETY DISORDER, PANIC DISORDER | H. LUNDBECK A/S (DK) | 2001-04-17 | — | — | US | disclosed |
| EP-0765311-B1 | 4-ARYL-1-(INDANMETHYL, DIHYDROBENZOFURANMETHYL OR DIHYDROBENZOTHIOPHENEMETHYL)PIPERIDINES, TETRAHYDROPYRIDINES OR PIPERAZINES | LUNDBECK & CO AS H (DK) | 2000-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195356-A1 | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines | CNR1, TPH1, CNR2 | SMN1; SMN2 1956/4885NPC1 1187/4885RAB9A 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.